Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Alexi SuretteByong Hoon YooTallal YounisKara MathesonTarek RamehJaime SnowdonGillian BethuneKirill V RosenPublished in: Breast cancer research and treatment (2021)
This study could help identify patients with ErbB2-positive tumors that are at increased risk of disease relapse following NATs.